CNH Partners »

Halozyme Therapeutics shares owned by CNH Partners

Quarter-by-quarter ownership of Halozyme Therapeutics shares owned by CNH Partners from 13F filings

Historical chart of CNH Partners investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by CNH Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by CNH Partners

Quarter filed Position value Share count Share price at filing
2023-12-31 $122k 140k 0.87

More positions owned by CNH Partners

Karuna Therapeutics Ord
Splunk Note 1.125% 6/1 (Principal)
ImmunoGen
Albertsons Cos Common Stock (ACI)
Cerevel Therapeutics Hldng I (CERE)
United States Steel Corporation (X)
Wayfair Note 3.250% 9/1 (Principal)
PNM Resources (PNM)
Etsy Note 0.250% 6/1 (Principal)
Amedisys (AMED)
Array Technologies Note 1.000%12/0 (Principal)
Gores Holdings Ix Class A Com (GHIX)
Hess (HES)
Lci Inds Note 1.125% 5/1 (Principal)
Pioneer Natural Resources (PXD)

View all positions for CNH Partners

Top funds holding Halozyme Therapeutics

Wellesley Investment Advisors
Davidson Kempner Capital Management
Lazard Asset Management
Citigroup
Aviva
Citadel Advisors
D. E. Shaw & Co
Wells Fargo & Company
Readystate Asset Management
Tenor Capital Management
Wolverine Asset Management
Victory Capital Management
Jpmorgan Chase & Co
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
Shenkman Capital Management

View all funds holding Halozyme Therapeutics